Pandemic darlings Moderna, BioNTech are now on two different paths

1. BioNTech diversified into cancer drugs, seeing stock gains while Moderna struggles. 2. Moderna's dependence on vaccines raises concerns about future revenue stability. 3. Both companies to report quarterly results soon, impacting investor sentiment. 4. BioNTech's partnerships could enhance its market position amidst competitive pressures. 5. FDA's evolving stance on vaccines complicates Moderna's future growth.